Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

prostate-specific membrane antigen

  • You have access
    177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
    Thorsten Derlin, Liam Widjaja, Rudolf A. Werner and Frank M. Bengel
    Journal of Nuclear Medicine January 1, 2023, 64 (1) 54-58; DOI: https://doi.org/10.2967/jnumed.122.264293
  • Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer
    You have access
    Validation of 18F-rhPSMA-7 and 18F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer
    Markus Kroenke, Lilit Schweiger, Thomas Horn, Bernhard Haller, Kristina Schwamborn, Alexander Wurzer, Tobias Maurer, Hans-Jürgen Wester, Matthias Eiber and Isabel Rauscher
    Journal of Nuclear Medicine December 1, 2022, 63 (12) 1809-1814; DOI: https://doi.org/10.2967/jnumed.121.263707
  • The PRIMARY Score: Using Intraprostatic <sup>68</sup>Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis
    You have access
    The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis
    Louise Emmett, Nathan Papa, James Buteau, Bao Ho, Victor Liu, Matthew Roberts, James Thompson, Dan Moon, Gemma Sheehan-Dare, Omar Alghazo, Shikha Agrawal, Declan Murphy, Phillip Stricker, Thomas A. Hope and Michael S. Hofman
    Journal of Nuclear Medicine November 1, 2022, 63 (11) 1644-1650; DOI: https://doi.org/10.2967/jnumed.121.263448
  • Robot-Assisted Prostate-Specific Membrane Antigen–Radioguided Surgery in Primary Diagnosed Prostate Cancer
    You have access
    Robot-Assisted Prostate-Specific Membrane Antigen–Radioguided Surgery in Primary Diagnosed Prostate Cancer
    William Gondoputro, Matthijs J. Scheltema, Alexander Blazevski, Paul Doan, James E. Thompson, Amer Amin, Bart Geboers, Shikha Agrawal, Amila Siriwardana, Pim J. Van Leeuwen, Matthias N. van Oosterom, Fijs W.B. Van Leeuwen, Louise Emmett and Phillip D. Stricker
    Journal of Nuclear Medicine November 1, 2022, 63 (11) 1659-1664; DOI: https://doi.org/10.2967/jnumed.121.263743
  • Prostate-Specific Membrane Antigen Radioligand Therapy Using <sup>177</sup>Lu-PSMA I&amp;T and <sup>177</sup>Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
    You have access
    Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
    Christiane Schuchardt, Jingjing Zhang, Harshad R. Kulkarni, Xiaoyuan Chen, Dirk Müller and Richard P. Baum
    Journal of Nuclear Medicine August 1, 2022, 63 (8) 1199-1207; DOI: https://doi.org/10.2967/jnumed.121.262713
  • <sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study
    You have access
    18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study
    Harun Ilhan, Markus Kroenke, Alexander Wurzer, Marcus Unterrainer, Matthias Heck, Claus Belka, Karina Knorr, Thomas Langbein, Isabel Rauscher, Nina-Sophie Schmidt-Hegemann, Kilian Schiller, Peter Bartenstein, Hans-Jürgen Wester and Matthias Eiber
    Journal of Nuclear Medicine August 1, 2022, 63 (8) 1208-1214; DOI: https://doi.org/10.2967/jnumed.121.262861
  • Effects of <sup>225</sup>Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
    You have access
    Effects of 225Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
    Dong Yun Lee and Yong-il Kim
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 840-846; DOI: https://doi.org/10.2967/jnumed.121.262017
  • 
    A Comprehensive Assessment of <sup>68</sup>Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
    You have access
    A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
    Monica Abghari-Gerst, Wesley R. Armstrong, Kathleen Nguyen, Jeremie Calais, Johannes Czernin, David Lin, Namasvi Jariwala, Melissa Rodnick, Thomas A. Hope, Jason Hearn, Jeffrey S. Montgomery, Ajjai Alva, Zachery R. Reichert, Daniel E. Spratt, Timothy D. Johnson, Peter J.H. Scott and Morand Piert
    Journal of Nuclear Medicine April 1, 2022, 63 (4) 567-572; DOI: https://doi.org/10.2967/jnumed.121.262412
  • The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
    You have access
    The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
    Liang Dong, Yun Su, Yinjie Zhu, Mark C. Markowski, Mei Xin, Michael A. Gorin, Baijun Dong, Jiahua Pan, Martin G. Pomper, Jianjun Liu, Kenneth J. Pienta, Wei Xue and Steven P. Rowe
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 248-252; DOI: https://doi.org/10.2967/jnumed.121.262411
  • Kidney Doses in <sup>177</sup>Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
    You have access
    Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
    Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowsha, Tumelo C.G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer and Juri Ruf
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 253-258; DOI: https://doi.org/10.2967/jnumed.121.262245

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire